Tag: allergy treatment
Mabylon AG Initiates Phase I Clinical Trial of Lead Compound MY006 for the Treatment of Peanut Allergy
— First study participant dosed in U.S. trial with healthy volunteers and patients with peanut allergy
— Novel, human-derived, half-life extended tri-specific monoclonal antibody to prevent allergic reactions
Mabylon AG, a leader in the high-throughput discovery, engineering, and development of human-derived antibodies for the treatment of allergies, neurodegenerative diseases, and inflammation, today announced that the first healthy volunteer has been dosed in the first-in-human clinical trial evaluating MY006, a novel tri-specific monoclonal antibody for the prophylactic treatment of peanut allergy. MY006 is based on patient-derived antibodies and designed to provide a new approach for preventing allergic reactions in individuals with peanut allergy.
Mabylon AG Raises CHF 30 Million to Advance Peanut Allergy Lead Program MY006 to Clinical Proof-of-Concept
— Funding combines equity investment and convertible loan
— Focus on best-in-class, clinical-stage peanut allergen neutralizing antibody
— Further potential for developing Mabylon’s discovery and pre-clinical pipeline programs
— Thomas Hecht has joined Board of Directors
Mabylon AG, a leader in the high-throughput discovery, characterization, and development of human-derived antibodies, today announced that it has raised a total of CHF 30 million (USD 37 million) to further develop its clinical-stage lead candidate MY006 and advance its early-stage pipeline. The funding combines a capital increase and a convertible loan of CHF 15 million, respectively. The funds are provided by Mabylon’s existing private investors, with the major investment coming from former management and board members of Roche. Read more…